2 completed, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow MLN2238: new trials by email Literature Review of MLN2238 trials Research Report on MLN2238
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 | |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis Daratumumab, Dexamethasone, Ixazomib - Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis | Phase 1 | Completed | M.D. Anderson Cancer Center | 21 | 2018-02-07 | 2026-07-09 |
Multiple Myeloma (2) · Immunoglobulin Light-chain Amyloidosis (1)
M.D. Anderson Cancer Center (1) · Multiple Myeloma Research Consortium (1) · National Cancer Institute (NCI) (1)
United States (2)
Hearn J Cho, M.D., Ph.D. (1) · Oren Pasvolsky (1) · Taiga Nishihori (1)
UM1CA186644 (1)